Opinion|Videos|March 24, 2025
Balancing Benefits and Risks: Patients’ Experiences With Newer Therapies and Side Effects in Late-Line RRMM
Author(s)Saad Usmani, MD, Amrita Krishnan, MD
Panelists discuss how physician-patient conversations about newer multiple myeloma therapies have evolved to include detailed discussions of potential benefits (higher response rates, novel mechanisms of action) alongside unique toxicity profiles (cytokine release syndrome with immunotherapies, neurotoxicity with CAR-T, skin/nail issues with GPRC5D-targeted agents), with patients sharing diverse experiences ranging from minimal side effects to significant complications that required hospitalization, emphasizing the importance of thorough preparation, proactive management strategies and realistic expectations when embarking on these innovative but potent treatment approaches.
Advertisement
Video content above is prompted by the following:
- How has your doctor discussed the potential benefits and risks of newer therapies, and what has been your experience with side effects?
Advertisement
Related to this article
Medicare will move ostomy supplies to eight national contracts in 2028. Survivors and clinicians say a poor fit can lead to leaks, infection and hospital stays.
An experimental treatment has kept one patient with heavily pretreated hairy cell leukemia free of detectable disease for more than two years, raising questions about whether CAR T-cell therapy could offer a path toward a cure.
The National Comprehensive Cancer Network released its first patient guideline written for caregivers on Oct. 27, 2026. The free guide covers emotional support, money, legal questions, medical tasks and caregivers' own well-being.
Three phase 3 trials presented at the 2026 ESMO Congress looked closely at swallowing, daily functioning and blood counts in throat, kidney and colorectal cancer. Here is what they found about living well during and after treatment.
New research found that nearly 1 in 5 second-level appeals for denied cancer medications under Medicare Part D were successful, raising questions about how insurers make coverage decisions and what patients can do when their treatment is denied.
Joy Maulik, MSN, FNP-C, explains why a prostate cancer diagnosis should be seen as a change in direction, not an ending, and how patients can lean on education, their providers and caregivers.
Dr. Morana Vojnic answers common questions about brain cancer, including diagnosis, tumor types, treatment effects, recurrence and life after treatment begins.
A national survey study of about 200,000 adults, published in Supportive Care in Cancer, found that people caring for someone with cancer had 89% higher odds of frequent mental distress than people who were not caregivers.
Advertisement
Advertisement
Trending on CURE
1
3 Quality-of-Life Results From ESMO 2026 Patients Should Know
2
4 Long-Term Survival Results From ESMO 2026 Patients Should Know
3
3 ESMO 2026 Results in Endometrial and Breast Cancer to Know
4
Neuro-Oncologist Answers Common Questions About Brain Cancer Diagnosis and Treatment
5